Natera Organ Health

🥇 Sandra Carey, PhD, landed another best of show today with the poster titled Enhancing the Utility of Antibody Testing with Donor-Derived Cell-Free DNA Post-Heart Transplantation. Nice work, team! 👏

Exciting news out of #ATC2024Philly! Natera's poster titled Extremely Elevated dd-cfDNA Post Heart Transplant: A Critical Result Case Review Series, presented by Sandra Carey, PhD, associate medical director at #Natera, received best of show! 🏆 ATC attendees can visit poster 70 to hear Dr. Carey present these findings today at 2:30 PM ET. Congratulations to all involved! 👏 See the full details of our 18 presentations and special events at the American Transplant Congress (ATC): https://ow.ly/C39a50S7i3R

Can't make our presentation at ATC 2024? Hear new Prospera surveillance data from the #ProActive Study in this 45-minute webinar followed by a 15-minute live Q&A session. For full details and to register visit: https://ow.ly/Yoz050S4xTX

ATC 2024 Attendees: Did you miss Natera’s Scientific Posters? Fear not, our upcoming webinar will bring you the in depth presentation by Phil Gauthier, MD, Senior Medical Director at Natera. Learn about three new data presentations from the ProActive Study, the largest prospective donor-derived cell-free DNA (dd-cfDNA) study in kidney transplant recipients, findings from two posters evaluating donor-derived cell-free DNA in multi-organ recipients from the MOTR Study and more. Sign up here 👇 https://ow.ly/3EqM50S4ueQ American Transplant Congress (ATC) #ATC #ATC2024 #cfDNA #Natera #ProActiveStudy #Transplant #KidneyTransplant

Now published | The recently published ProActive study demonstrates how #Natera's Prospera Transplant Assessment test predicted antibody-mediated rejection up to five months and T cell–mediated rejection up to two months in advance of biopsy-proven rejection. Read the full study: https://ow.ly/hrFx50S2isZ #ProsperaKidney #Transplant #ClinicalResearch #cfDNA

#ATC2024Philly is this weekend! Natera and its collaborators will present 18 abstracts highlighting new Prospera data across heart, lung, kidney, and multi-organ transplantation. This includes an oral presentation highlighting the predictive capabilities of the Prospera Kidney test from the ProActive study, the largest prospective dd-cfDNA study in kidney transplant recipients. “We look forward to sharing new research at ATC that demonstrates the breadth of clinical evidence supporting Prospera across multiple organ types,” said Sangeeta Bhorade, MD, chief medical officer of organ health at Natera. “This includes new data from the landmark ProActive study, reinforcing the value of the Prospera Kidney test as a highly accurate surveillance tool for detecting ongoing organ rejection and predicting future rejection.” https://ow.ly/oFeC50S2tbJ

We're ready for #ATC2024Philly! Join us for a robust schedule of events, presentations and opportunities to hear about the latest data supporting Prospera, as well as Natera's innovation in transplantation. American Transplant Congress (ATC) #Natera #Prospera #TransplantCare #KidneyTransplant #ATC

The recently published ProActive study demonstrates how #Natera's Prospera Transplant Assessment test predicted antibody-mediated rejection up to five months and T cell–mediated rejection up to two months in advance of biopsy-proven rejection. Read the full study. https://ow.ly/sNBz50ROHGr #ProsperaKidney #Transplant #ClinicalResearch #cfDNA

Today's the day! We're thrilled to be at National Kidney Foundation's Spring Clinical Meetings! Check out our poster presentations Wednesday, May 15 and our reception on Thursday, May 16. To RSVP to the reception, please email kkam(at)natera(dot)com. Can’t attend the reception but would like to meet in person? Find us at booth #202 during exhibit hours. #Nephrology #NKFClinicals #NKF2024 #SCM24

The ProActive study is the largest prospective dd-cfDNA study in kidney transplant recipients, with roughly 5,000 patients enrolled at 54 participating transplant centers. This study, published in Transplantation Journal, supports real-world performance of #Natera’s Prospera Kidney test to detect all forms of rejection and help inform treatment. Read the full announcement: https://ow.ly/PHeE50RogF8 #Transplant #ddcfDNA